Cargando…

ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI)

OBJECTIVE(S): This study evaluated the interaction of anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) in predicting sustained clinical response in an observational registry of patients with rheumatoid arthritis (RA) followed in routine practice. METHODS: Patients with RA enrolle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pope, Janet E, Movahedi, Mohammad, Rampakakis, Emmanouil, Cesta, Angela, Sampalis, John S, Keystone, Edward, Thorne, Carter, Bombardier, Claire
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241994/ https://www.ncbi.nlm.nih.gov/pubmed/30487995 http://dx.doi.org/10.1136/rmdopen-2018-000738

Ejemplares similares

Impact of residential area on the management of rheumatoid arthritis patients initiating their first biologic DMARD: Results from the Ontario Best Practices Research Initiative (OBRI)
por: Movahedi, Mohammad, et al.
Publicado: (2019)

Impact of the COVID-19 pandemic on patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative (OBRI)
por: Wong-Pack, Matthew, et al.
Publicado: (2023)

Correction: ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI)
Publicado: (2019)

Effect of nurse-led care on outcomes in patients with ACPA/RF-positive rheumatoid arthritis with active disease undergoing treat-to-target: a multicentre randomised controlled trial
por: Hoeper, Juliana Rachel, et al.
Publicado: (2021)

Measuring ACPA in the general population or primary care: is it useful?
por: Finckh, Axel, et al.
Publicado: (2020)

Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population
por: Haraoui, Boulos, et al.
Publicado: (2015)

Standardisation of ACPA tests: evaluation of a new candidate reference preparation
por: Van Hoovels, Lieve, et al.
Publicado: (2022)

Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis
por: Joshua, Vijay, et al.
Publicado: (2020)

Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry
por: Bergstra, Sytske Anne, et al.
Publicado: (2019)

Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study
por: Haraoui, Boulos, et al.
Publicado: (2022)

Association between RANK, RANKL and OPG polymorphisms with ACPA and erosions in rheumatoid arthritis: results from a meta-analysis involving three French cohorts
por: Ruyssen-Witrand, Adeline, et al.
Publicado: (2016)

High Adherence to System‐Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years
por: Barber, Claire E. H., et al.
Publicado: (2018)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set
por: Bykerk, Vivian P, et al.
Publicado: (2016)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis
por: Accortt, Neil A., et al.
Publicado: (2018)

Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis
por: Scott, I C, et al.
Publicado: (2016)

A new classification of HLA-DRB1 alleles based on acid–base properties of the amino acids located at positions 13, 70 and 71: impact on ACPA status or structural progression, and meta-analysis on 1235 patients with rheumatoid from two cohorts (ESPOIR and EAC cohort)
por: Ruyssen-Witrand, Adeline, et al.
Publicado: (2015)

Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)
por: Cohen, Stanley B, et al.
Publicado: (2021)

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment
por: Alten, Rieke, et al.
Publicado: (2014)

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
por: Keystone, Edward C, et al.
Publicado: (2018)

Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study
por: Thorne, Carter, et al.
Publicado: (2018)

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis
por: Akdemir, Gülşah, et al.
Publicado: (2018)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study
por: Kubo, Satoshi, et al.
Publicado: (2023)

Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative
por: Li, Xiuying, et al.
Publicado: (2022)

Management of Fatigue in Rheumatoid Arthritis
por: Pope, Janet E
Publicado: (2020)

Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?
por: Mongin, Denis, et al.
Publicado: (2019)

Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data
Publicado: (2018)

Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
por: Emery, Paul, et al.
Publicado: (2020)

Serum calprotectin levels do not predict subsequent relapse in rheumatoid arthritis in remission: a post-hoc analysis of STRASS study
por: Romand, Xavier, et al.
Publicado: (2023)

Identification of Distinct Disease Activity Trajectories in Methotrexate‐Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty‐Four Months
por: Bykerk, Vivian P., et al.
Publicado: (2021)

Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift
por: Chatzidionysiou, Katerina, et al.
Publicado: (2019)

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
por: Paulshus Sundlisæter, Nina, et al.
Publicado: (2022)

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6
por: van Vollenhoven, Ronald F., et al.
Publicado: (2018)

Smoking‐Related Mortality in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study Using the Clinical Practice Research Datalink
por: Joseph, Rebecca M., et al.
Publicado: (2016)

Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2020)

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
por: Chatzidionysiou, Katerina, et al.
Publicado: (2016)

Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts
por: Westerlind, Helga, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k35k5es3jehh88pgh282c6jruf